期刊文献+

Simultaneous determination of sunitinib and its active metabolites N-desethylsunitinib(SU12662) in nude mice plasma by liquid chromatography tandem mass spectrometry and its application to a pharmacokinetic study 被引量:1

液相质谱串联法同时测定舒尼替尼及其活性代谢产物SU12662在BABL/c裸鼠血浆中的浓度及其药物动力学研究(英文)
原文传递
导出
摘要 A sensitive, rapid, and simple liquid chromatography tandem mass spectrometry(LC-MS/MS) method for simultaneous determination of sunitinib and its active metabolites in plasma of BABL/c nude mice was developed and validated. Plasma samples were pre-treated by protein precipitation with pazopanib and used as an internal standard. Separation was performed on a reversed phase C18 column with a mobile phase composing of 10 m M ammonium formate p H 3.25(adjusted with formic acid) and acetonitrile(65:35, v/v) at a flow rate of 0.5 mL /min. Triple quadrupole tandem mass in multiple reaction monitoring(MRM) mode with electrospray positive ionization was used to monitor all the compounds. The current LC-MS/MS method was highly selective and sensitive with lowest limit of quantitation(LLOQ) of 0.5 ng/mL for both analytes and reliable intra- and inter-day precision and accuracy validated by relative error(RE%) and relative standard deviation(RSD%). Linearity of calibration curve was excellent(r0.99) within a concentration range of 0.5–1000 ng/mL. This method was successfully applied to a pharmacokinetics study on BABL/c nude mice given with single dose of oral administration of sunitinib at 20 mg/kg. 本研究建立并验证了一种灵敏、快速、简单的液质联用方法,用于同时测定BABL/c裸鼠血浆中舒尼替尼及其活性代谢产物SU12662的药物浓度。血浆样品采用蛋白沉淀方法处理,并使用帕唑帕尼作为内标。采用C18反相柱进行分离,流动相为10 mM甲酸胺–乙腈(65:35,v/v,pH 3.25),流速0.5 m L/min。所有化合物均采用电喷雾电离源,正离子方式检测。舒尼替尼及SU12662的最低定量下限均为0.5 ng/m L,线性范围均为0.5–1000 ng/m L(r>0.99)。该方法对舒尼替尼及SU12662的测定均具有良好准确度以及可靠的日内、日间精密度,方法稳定性良好,无明显基质效应。此方法成功用于BABL/c裸鼠口服20 mg/kg舒尼替尼的药物代谢动力学研究。
出处 《Journal of Chinese Pharmaceutical Sciences》 CAS CSCD 2015年第4期217-224,共8页 中国药学(英文版)
基金 National Natural Science Foundation of China(NSFC,Grant No.81473277)
关键词 LC-MS/MS Sunitinib SU12662 Nude mice Pharmacokinetics 液质联用 舒尼替尼 SU12662 裸鼠 药物代谢动力学
  • 相关文献

参考文献29

  • 1Mendel, D.B.; Laird, A.D.; Xin, X.; Louie, S.G.; Christensen, J.G.; Li, G.; Schreck, R.E.; Abrams, T.J.; Ngai, T.J.; Lee, L.B.; Murray, L.J.; Carver, J.; Chan, E.; Moss, K.G.; Haznedar, J.O.; Sukbunthemg, J.; Blake, R.A.; Sun, L.; Tang, C,; Miller, T.; Shirazian, S.; McMahon, G., Cherrington, J.M. Clin. Cancer Res. 2003, 9, 327-337.
  • 2Abrams, T.J.; Lee, L.B.; Murray, L.J.; Pryer, N.K.; Cherrington, J.M. Mol. Cancer Ther. 2003, 2, 471-478.
  • 3van Erp, N.P.; Gelderblom, H.; Guchelaar, H.J. Cancer Treat. Rev. 2009, 35, 692-706.
  • 4Faivre, S.; Delbaldo, C.; Vera, K.; Robert, C.; Lozahic, S.; Lassau, N.; Bello, C.; Deprimo, S.; Brega, N.; Massimini, G.; Armand, J.P.; Scigalla, P.; Raymond, E. J. Clin. Oncol. 2006, 24, 25-35.
  • 5Chouhan, J.D.; Zamarripa, D.E.; Lai, P.H.; Oramasionwu, C.U.; Grabinski, J.L.J. Oncol. Pharm. Pract. 2007, 13, 5-15.
  • 6Varna, M.; Bousquet, G.; Ferreira, I.; Goulard, M.; E1-Bouchtaoui, M.; Artus, P.M.; Verine, J.; de Kerviler, E.; Hemandez, E.; Leboeuf, C.; Escudier, B.; Legres, L.; Setterblad, N.; Soliman, H.; Feugeas, J.P.; Janin, A. Bertheau, P. Int. J. Clin. Exp. Pathol. 2014, 7, 2950- 2962.
  • 7Li, X.; Tong, L.J.; Ding, J.; Meng, L.H. Cancer Lett. 2014, 342, 159-166.
  • 8Schem, C.; Bauerschlag, D.; Bender, S.; Lorenzen, A.C.; Loermann, D.; Hamann, S.; Rosel, F.; Kalthoff, H.; Gluer, C.C.; Jonat, W.; Tiwari, S. BMC Cancer. 2013, 13, 32.
  • 9Fratto, M.E.; Imperatori, M.; Vincenzi, B.; Tomao, F.; Santini, D.; Tonini, G. Clin. Ter. 2010, 161, 475-482.
  • 10Abdel-Aziz, A.K.; Shouman, S.; E1-Demerdash, E.; Elgendy, M.; Abdel-Naim, A.B. Chem. Biol. Interact. 2014, 217, 28-40.

同被引文献3

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部